An open label study to investigate the safety and efficacy of abacavir/lamivudine/dolutegravir and the pharmacokinetic profile of dolutegravir in HIV infected patients of 60 years of age and older

Trial Profile

An open label study to investigate the safety and efficacy of abacavir/lamivudine/dolutegravir and the pharmacokinetic profile of dolutegravir in HIV infected patients of 60 years of age and older

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2018

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 May 2018 Results (n=43) assessing abacavir/lamivudine/dolutegravir in patients with HIV-1 infection, were published in the Clinical Infectious Diseases.
    • 28 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 11 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top